IMNN - Earnings call transcript Q4 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Dave, and I will be your operator today. At this time, I would like to welcome you to Imunon's 2023 Financial Results Conference Call. [Operator Instructions]I would now like to turn the call over to Kim Golodetz. Please go ahead.

Kim Golodetz

morning, good and you, everyone. Thank Golodetz This LHA. is Kim with Results Update Conference to Imunon's Business Financial XXXX Welcome Call. and

can forward-looking live the future today's During no over update call, the and In would results content by about broadcast, March from Imunon's expressions. as other expect, management Imunon's said, Michael forward-looking the be that anticipates, accurate materially general, that words Commission. These during conference be to statements events. believes of expectations this comments the such of making statements guaranteed, by will and is forward-looking including XX, as call uncertainties, current call periodic risks forth undertakes XXXX. company's I regarding subject in may and Executive except statements.I differ expectations Michael? obligation statements or Exchange of the are are made only to identified caution and required can similar the actual turn of based also revise Securities call as this filings statements with those law.With No on or such number Chairman. to be Tardugno, like and projections date set to a Imunon

Michael H. Tardugno

you, of be morning, you. Thank Kim, everyone. all good to here with and It's good

anticipated immunotherapy its Medical our Joining Hazard me and today ovarian are in will or Jeffrey cancer. Financial of Officer; Officer. advanced Dr. Chief IL-XX about Church, Sebastien Hazard, the Chief and our speak treatment IMNN-XXX, place

X Dr. of during other leadership she opportunities. prepared end grateful to no sure you, Corinne key I'm her want departure I session her for wholly We growth, to where are of departure her our TheraPlas technology in based our our impacts remain the IMUNON pursue wish the earlier with on study TheraPlas X PlaCCine way plans advancing and But remarks. the you're remain that's study tenure. Dr. platforms, aware Phase platform that made her our on this to We for which business Chief initiate her our first, Anwer In and is reassure addition, I Alabama, is X Institute who and PlaCCine. to month HudsonAlpha IMNN-XXX, during well of of all Khursheed Le technology. Goff OVATION concept in and the of our to Science vaccine seasonal a complete we just joins Officer, center on based to available at track Huntsville, our Phase the be will from committed however, our COVID-XX that Anwer, Q&A Dr. research and IMNN-XXX, us contributions

IND will interim product our we we Hazard speaking of drafting study, in of for strategy on these soon. FDA submission expect for this an be the month, III past announced the protocol a be We'll data more the Meanwhile, the well. in preliminary data this the From minute. application line with conversations platforms mid-XXXX. XXX. study and the for Our Phase FDA, with Dr. about Based OVATION to unchanged as development top report X remains

expect And year. to of quarter we're in ready the go. the in by begin we study acceptance second patients Following I Phase this agency, to this enrolling

contracts approved, IRB both in Both biological at committees the been are sites X in identified DM and institutions or our conditionally identified We're Philadelphia. to process. research have clinical They've and have pending approved sites in submitted X the protocol. acceptance, have go. place in FDA We the Beth ready Israel the protocol Boston institutions to safety

to and some like Dr. turn the forward first, call look the the the study. I'd the So to agreement we look talk initiating I'll But vaccine forward with to about over submission agency's more program. Hazard. to Sebastien? IND

Dr. Sebastien Hazard

everyone. Hello, Thank very much, Michael. you

should vision want considerations our trial interim X on to look discuss what a data share like hold I and pivotal Phase for I could some of review we've Before the some generated the data XXX, up.

you is an is standard ovarian chemotherapy. study, tested with randomized interim progression, DNA-based set survival full perioperative XX, intent-to-treat know, we newly September we patients XXX XXX progression combination overall and cancer death a population, reached free survival for of showed arm. of robust months. control diagnosed in delay mature the XXX this efficacy followed showing advanced treatment a And in and than XX, the approximate in showing X similar improvement immunotherapy. IL-XX the a reported This or patients. later, treatment in OS being a evaluating data, As OVATION is X the data still promising particularly treatment to for enrollment a more confirm signal. the year care of overall In disease of X-month data September trend, the preliminary to survival. our It arm arm data over needs in

subset for maintenance data patients treated ovarian When cancer. a inhibitors we study, We in OVATION part yet treatment time inhibitors. the of first of PARP also first-line the on not dig PARP reported X with were

Now months XX.X they subgroup, arm or A an control X first with treatment post-chemo larger In benefit. inhibitors patients important survival received the median in PARP plan. maintenance clinical was therapy XX.X arm months an analysis versus form the months even longer. the of in who this suggest patient's part subgroup with XXX of the progression

tolerability small setting. in not the overall the Also In in addition, and the continue the they reached analysis median arm XXX a XXX months are from intriguing. show XX.X arm. Safety of control patients, in data this was number survival good of to

So may production possible the the We of This cancer. our hands, Phase shown environment effective OVATION immunotherapy we ovarian in very program first there X by study. think is the now. for I tumor as our on in technology TheraPlas by made treatment of right allowing are IL-XX micro well the this thoughts durable

perioperative X of confirm data cancer ovarian activity. XX's believe XX positioning very is Ovation patients the with that to of important. in So clinical the data far, from the X Ovation XX We treatment the preliminary of

In immunotherapy the most administered can when addition of of patients, local lack by the the immune for harnessing the to these the stage tumor in system a this have the locally options the is environment. micro disease impact

on Assuming enough preclinical one angiogenic. midyear registration to submit Phase similar provide ongoing it Breakthrough plans the with the the and efficacy inclusion Cancer study is the And is II PFS their synergy Bevacizumab, being in in about the enrollment offer patients. data XXX step help from XXX as our more receiving by patients bevacizumab the setting. were to benefit the bevacizumab FDA.Several important setting results, It steady perioperative has will study of during Ovation experiments. would patients around the bevacizumab the internally, to excluded for making and also the Foundation next X, these trial the maturity periodic the shown frequently are synergistic most even using discussion with used XX% sites is of done you in clinical as patients. approximately allow also to of of data combination in on safety know, And more This with may efficacy attractive combination. considerations

in diagnosed design, a representing ovarian the PARP to this may study with most likely to or the around XX% is patients. the who inhibitor focus be a tumor deficiencies the introduce consideration to XXX subpopulation, exposed possibility newly test cancer the homologous are of recombinant maintenance. efficacy Another on in HRD, We in

collaboration study second Foundation Cancer Now Phase enrollment ongoing. X in breakthrough our in with is

is combination or final the bevacizumab The cancer joined first randomized of will announced of Center. study. Sloan later combination. of trial's sites. safety primary detection MD XXX Cancer are will other minimal has with in under-evaluated patients patients in are to Memorial Avastin. and microenvironment secondary bevacizumab Kettering the impact endpoint This An look quarter at understand provide XX trial to allow MRD. X enroll better been measure of better second to data Texas within on the of at proof Stage X/X This we XXX confirm is have or study enrollment by for cancer. is is University Initial the in XXX X treated to expected It stage following of that of approximately Anderson disease, study the evaluating of translational second Bevacizumab enrollment ovarian assess the with and to new concept Initially, progression-free endpoint ctDNA first And this combination tumor for survival. PFS several of The this laparoscopy XX, residual year look, the and expected laparoscopy Adjuvant a somewhat completion. data completion the like include expected understand trial endpoints and MRD, methods years important combined with the ovarian

We added. as continue will sites you keep be to updated

Michael. call of ovarian cancer So I'll our over with review back to turn that the program,

Michael H. Tardugno

us show joined wealth great of in he ovarian regulatory recently, And Hazard say cancer Sebastien. for with to you... Dr. research, I a him Thank of record has the that's want promise. affairs, brings just experience beginning to clinical and deal a and

We delighted. of can't benefit will I in your that sure Thank short the And say enough you, Sebastien. impact period you our time. shareholders for very company had the from your and are I'm expertise...

to little the about So a durability. I talk want more bit

going You're that morning. to hear the of through course conversation the this

similar an product and a over our advantage key is technology candidates. durability Our of characteristic

Our prolonged to technology tumor by for illustrated the for exposure Hazard, the the the body of allows of which IL-XX. in durable a allows protein as production Dr. IMNN-XXX, microenvironment

protection the from and target sustained antigens pathogen, pathogen the well provided the approximate MR against months beyond vaccine provide A platforms. that production we X a Before vaccine that allows will the by this is the expect of durability

that, expert with So the here. I'm not

line. our durability experience us could Dr. mechanism you're the the So bit little on tell with you Would about so more -- and characteristic? Anwer, far you a this

Khursheed Anwer

Sure, Khursheed. Michael. is This

is the pathogen by therapeutic drugs an IL-XX, on after of vaccine. The attribute you of at as a same is the of your important to local said, difference that for drug cell setting, entry. vaccine persistence agent, is durability injection is determined a level Michael, the persistent product stability for tumor only the true a site And or imperative is oncology that The in an antigen. keep pressure a is after vaccine tumor. and the drug a whether such As

the your for and Now in the of pathogen is of answer a product our our vaccine product molecule addressing challenges. expression or bioavailability question, IL-XX persistent durable antigen approach a therapeutic our to mechanism in

product that that First is after DNA of the from the the stability degradation. administration delivery our proprietary system use protects addresses mechanism

bioavailability. higher there's So

cell mRNA protein longer or protein in last has longer. of the unlike DNA, antigen or the residence hence, therapeutics the time and Second, production

the our in increasing or the therapeutic are use whether mechanism. through of a Really, X sell longer the bioavailability is the DNA. a residence those mechanism of So vaccine durability, part a through nutshell, delivery and system and of key aspects time

Michael H. Tardugno

the Anwer remarks. Khursheed. prepared will you, our of end answer line Dr. the be on at to Thank questions

delivered and in continue that let's proprietary Anwer delivery promotes proprietary now Dr. discussion expression PlaCCine about. nonviral pathogen our synthetic So our plasma that spoke of DNA just on the antigens system based of vaccine

We XXX to are the that for delighted with report the of NDA an filing FDA.

proof-of-concept clinical will quarter a The COVID-XX are trial quite seasonal in We This hopeful, are subject FDA, been the the proposing robust. dialogue following XXXX, we vaccine. acceptance the booster between XX Dr. we is expected I agency has study by to a second Hazard begin Phase enrollment which as soon. of speak and

Our responses their to questions have very timely. been

quite The moving this study are and objective neutralizing vaccine safety, the well. things evaluate healthy is is of antibody adults primary in response. tolerability to So

durability, of evaluate a also will We the key and response durability characteristic.

durability. of the their in Based G is expression as accordance designed June guidance OmicronXBBX.X to durability to the published over study it's objectives of superior in evaluate protect XXXX. for preclinical of mRNA been the immunoglobulin to the variant or IMNN-XXX data, are has vaccine T to referred against ability in antibody second XXX with on published to FDA's activity cell elicit SARS-CoV-X data. be IgG and immune The expected

you data generated some and most XX%. As on better immunogenicity attributes may this protection of recall, compelling the importantly, vaccine, than preclinical we've

better protection sorry, And than XX%.

have shelf demonstrated Fahrenheit properties These and least and at month the or characteristics handling temperatures distribution compared at refrigerated life protein months when vaccines body X mRNA the or compared delivery, other PlaCCine We manufacturing fragile flexibility vaccines for DNA well degrees suggest responses, the compliance XX manufacturing XX cell vaccines, superior commercial safety, as with temperature. advantage and also at vaccines viral T superior in greater flexibility. more as or with

product? of So bit you of the back it you I'm little Anwer, a about messenger our and us to are compare we with RNA? and confident to Dr. going so stability contrast turn Can give why

Khursheed Anwer

less mRNA And temperature. kind minus to Yes, extreme countries, cold vaccines during underdevelopment all transportation, sure. the strict even XX much I we you developing temperature that have degrees. the minus to mean actually equipped storage with requirement when the very at that countries, That's country, not in use know provision. of just XX keep freezers, there pharmacies degree out, you came it condition have

vaccine. problem So it's disseminating a the

DNA pharmacy last a the long also to relative stability. And a So plus, of which There's is temperature, mRNA, has delivery I a mRNA. working more more could and as before, refrigerated more very for it's time temperature. because it the provides at of stable, period protective stable use almost every system had mentioned than

the have intrinsic degrees, mRNA and of mRNA of temperature -- we actually, system the distinguishing just And DNA use really terms XX synthetic That for DNA. stability. stability. of provides it's at So month a versus in degradation a nature that limits of over feature the of keeps our vaccine seen delivery even

about it hours, it it's discarding putting nurses that pharmacy if temperature imagine people, duration to if -- goes a take beyond couple of out X the don't they delivery worry not hours. after it if -- or So have

we feel that sense. confident think I in So

that have vaccine and addressed in distribution We issue critical storage.

Michael H. Tardugno

Again, used demanding least its vaccine talking stable XX -- Thank I degrees some month. end temperatures Anwer the during makes patients And for that about of of Dr. really be X degrees remarks. handling at XX some are you... particularly that for equivalent more -- prepared for and Khursheed. Centigrade at very Again, available of for both to Khursheed the are was our realistic in preparation Fahrenheit, questions the the world in will countries. administration the at third

expected, look assuming partner reason believe development XXX out Following program as we to Phase to We'll the this I and the on expand study further to won't. no platform. it for have and performance

medical assuming For those technology I'd this we clinic, may we in party, that a of success are out, of as concerned who you to superiority add, the pointing bit are like late be the little to the also the viral pathogens as of has defense means and be with a course, vitally pandemic community address emerging potential. a in particular, the the the rapidly to evolving government, to to potential important agencies, to newly

that, I'll financials. Church to with our over of turn Jeffrey the a call So discussion for Jeff?

Jeffrey W. Church

financial included which our used at-the-market $XX Imunon's to million the interest XXXX before a decrease for XXXX. $XX.X used Imunon onetime Cash in expense this the Thank in of morning and $XX.X was resulted with year in the market Bank million loan, cash stock. in of in payment year. of amounted sale facility of convertible Valley Details we results million. the you, Form release opened. and in this the $X.X was This activities million is cash for first primarily activities investments. $X.X XXXX prior the XX-K, operating in by compares the company's million, Silicon press Michael. This quarter to sales $XX.X That $X.X million from $X.X million we offset to which due resulted subsequent from redemption equity under of financing year. are million payoff preferred of issued of Net ended filed and the the

As to on continue cash we strong have in the focus past, management. we will

loss loss million of share, a compares reported XXXX and Imunon Let our expenses a XX% results. were million or share this $X.XX million $XX.X from Operating me net last million, $X.X financial of of XXXX. $XX.X $XX year. of per for decrease review for turn a $X.XX a XXXX, with now or net per to

costs million, expenses the R&D due down very of specifically, de we development development items. down for $X.X associated year were million the from XXXX, $X.X for III the of CMC compared study with this with $X.X DNA prior and to Costs vaccine for was $X in well were $X.X of the capabilities breaking X last minimis Dr. associated as that clinical this major systems Phase study nanoparticle PlaCCine and due levels in year. enrollment, development XXXX. million And that's $X reported this XXXX from More associated manufacturing for OVATION technology line OVATION XXX consistent with the DNA the in in XXXX. million Research increased $XX.X million Costs expenses II million the these million to development pilot Now study, the Hazard the year. were million XXXX operating year, development support platform by plasmids as with costs of decline manufacturing costs, completion delivery and indicated to costs this the the OPTIMA $X.X to as were to September in-house year. compared XXXX. of

million announced strengthens New the $X.X we've XXXX. for decrease Investment nice company's were clinical compared expenses the regulatory Other this in we income NOL the short-term further primarily That D&O issues the noncash the losses nonoperating lower investments $X.X million. compared as very primarily million General we $X.X other with million insurance III Lower costs, to these ThermoDox. costs of risen sale unused was nonoperating and income for XXXX. Subsequent sales year and year, many to Jersey legal Phase stock attributable to This compares our compensation compared operating nondilutive received end XXXX are $X Our had costs in employee-related which net this million trial cost million year. to lower to million this our to also $XXX,XXX. sheet. cash contributed of were $XX.X XXXX of to proceeds from the with that of million last was $XX.X had lower for from administrative decrease. $X.X resolved source, net $X.X million funding $X.X year that year was this expense, balance expenses for a

retire the $XXX,XXX second to SVB In a had Hudson earlier, into to XXXX. the debt in paid Corporation. $XXX,XXX connection loan Finance XXXX, loan Valley and that we to facility, proceeds Technology with the $XXX,XXX incurred of of recognized we We with expense a quarter and used with We loan XXXX, extinguishment. Silicon of some we had facility previous June in the As Bank. in fees, end-of-term a facility and I Silicon off facility XXXX pay mentioned from entered early Valley the loan Bank termination we compared terminated that In facility. on loss interest

had think more was was $X.X took million or I that offsetting expense some in-process $XX.X show that milestone onetime assets off requirements million a R&D in-process had earn-out sale we an then write-off to driver importantly, impairment the writing year's last in of not from of I preferred achieved. as big the gain operating the in because and the charge noncash $X.X you in and earlier, to And lastly, assets an we expenses a mentioned of due liability the of stock. then interest subsequent been million redemption nonoperating resulting

utilization us review, runway through Michael. $XX now time pretty takes providing period. call XXXX a XXXX I'll for cash Our million, is the that that approximately with With back turn us financial to the much

Michael H. Tardugno

Thank you, Jeff.

As lively of financials. always, discussion a our

January of unfair support micro-cap terms in felt S-X the In biotechs in with an we virtually unacceptable filed all which Imunon-like testing ongoing capital our year, market, were this of presented other we the to nonrevenue of was was and raise know, you our that to As programs. goal research shareholders.

footprint step So not favorable a so, cash until program, of some we sense. plan, we reducing Doing conditions nonessential our taken consequently, our responsible to however, financing have just conservation without makes is more for are the chosen market to and headcount programs defer have implement deferring a a there company.

is deep X have trials. medical of and harnessing to clinical power have just trust is a prepared our and research. team to want our will interest the I shareholders, emphasize ensure the the In agree through I your are of cash our goal the you to commitment capable readouts in closing best that that remarks, of focused we system. we So milestone that been our acting keenly employees and management our immune on that that has company my discussed

call work in cancer to employees up With for creating to place is diseases questions of. Operator? provide up or a questions. the of with your while goal that, for immunity our durable proud potent to that and Our be open more I'll very -- open can significant our of millions people value shareholders infectious

Operator

Instructions]. [Operator We will now begin the question-and-answer session.

Our question Partners. comes Global with Molloy Alliance from first James

James Molloy

is for Laura this actually Well, Jim. Sorel on

II well for For trial obtain think combination enrollment in conducting a as Phase readout an you'll you're the patient for that this trial? XXX as interim complete result do or Avastin, you first with look when

Michael H. Tardugno

over I'm and turn going question, I answering that Dr. to to maybe Hazard. start balance can the

the It's a been been one The many the program, is ways. generating patients is extent the patients difficult the -- has of which thing have great cancer been researchers do. interest this from eliminated So study. hypothesis primary individual very are who important a to with in to to has evaluating endpoint associated

is this change patients. if disease of So that for we're could any proposal treatment residual to idea here, it second a course evaluate of laparoscopy of successful minimal the

with the Avastin Daner-Farber So so under using now -- candidate Hopkins, the will MD be our of in Sloan enrolling. more product control watchful institutions institutions Anderson, country, Hartford, including premier in of we joining combination Memorial institutions the soon. some Johns X X the study quite Kettering, have

Yes think Sebastien? patients on trial. number we of I a have

Dr. Sebastien Hazard

Yes, trial. MD we first patients at the on site And have X based Anderson. on open

we one just mentioned, opened, and second we one more I Oklahoma the who Hopkins second expect Johns one being As University. being and the have X

safety would that very little the combination the course, large the One a pick objectives like data proof And and on to combination also enrollment is the of so on on this to of useful. take of efficacy, make we I these safety one if of that for will up. PFS. III The expect this there second will point we concept X are be time Phase start able But is a study, the bit because is, to the look at X will main here based sites, study. are

Michael H. Tardugno

your -- than to period next those the sites the in things. of So by approach patients because all X have this the sites are and second sites in the the novelty addition possibly expecting the of the a other on longer year we're establishing this Once study. anticipated of for end to XX the way, specifically, by we just among of largely primary enrollment been to board, question answer endpoint has

James Molloy

current to then have many environment Got it. helped? other your you potential describe regard and vaccine your And the discussions that partnership any maybe ongoing PlaCCine in of your might also you and candidates, how partnership

Michael H. Tardugno

-- are some arrived expressed an specifically data, have partnership for is think interest that the far environment. expect haven't well, new waiting off. any this yet I And we can clinical to most that I which Imunon at of not mean is vaccine institutions you

about this well potential Our talked big right technology superiority, to. a is The by now this that in are But recognized novel. call that them. sidelines are handful and pharma in this, we we've continued the each talked engaging institution with updates, morning, for is asking that I the think, every of are there and we on companies

I to they some potential the only exciting not governments. of mean of talked whether think too or I me, they're government. are however, much even pandemics, I compromise patients collaborators potential don't agencies most know for organic have economies though, if this, the we've but -- be the otherwise, but the probably the to about and

So the a for is that a respond virulent DoD, effective able that be more objective are of vaccine to with BARDA. -- really to quickly potent or to evolving having critical example, in a and means an idea way emerging viruses the emerging

I some clinical expect again, once we preliminary data, to those have partnerships, mature. So

Operator

The from next Small Cap. with David Zacks comes question Bautz

David Bautz

update the morning. for Thanks this

and vaccine durability I the longitudinal XXX discussion are volunteers treatment. in programs through you IL-XX on the you are protein XXX, of program, measuring as the looking actually in both PlaCCine, patients call. to the going your spike you expression So in expression it measuring of I with these will -- for healthy kind to off earlier kind in for from And be of regards Phase keying of want that Curious start then study? move at off

Michael H. Tardugno

That's Dr. line? you still Anwer, are a Khursheed, the on great question.

Khursheed Anwer

Yes, I am, Michael.

a good that's question. David, So

have the For IL-XX, previous product. clinical tiles, major administration the after IL-XX we of in repeated

recall, As is once week weeks. you every several may for XXX given

respect of baseline. protein, that in we So quantified increases to IL-X after the ensure have With antigen studies done if we as and have blot the that multiple over protein is we spike well. is the examined molecular produced. to spike mRNA-based to characterization have quantification treatment But the that levels animal is in properly Weston we that But on mRNA blot a models, most see weight. of size analysis for have protein our Western the

David Bautz

FDA to that the look require ? Is at of is protein in spike of levels the not is the expression in? they're you that -- Or something the going the to interested

Khursheed Anwer

No, not spike has clinical in FDA consistent as that In measure demonstration the the is not that human other I require well? mean required. literature. antigen the of response does been the it's trials production. and trials, you pretty levels, reflective protein to You of antibody

the in clinical So it's the spike not required to quantify trials. protein

David Bautz

Okay. Great.

seen I'm any bit. those product? that going little or partnering gears one in saw a you've sure of this switching if their So are I news you discussions, an for curious asset. interest IL-XX just Gilead, how kind the morning about partnership for

Dr. Sebastien Hazard

asset. as having a data mean, with know, verge of I in you our Phase Look, II this we are

you would our very data looking promising clinical that parties we third confirmation. We potential have interested at have are tell already that can data. some be in I when there

of that a this this so possibility develop we And course, is asset. partnerships on

Michael H. Tardugno

contacted Gilead, to have so. I mean do I not as the list say specifically they that by They are for have to been yet. on us

David Bautz

of to Okay. want in XXX look considered to just the up data study, the exactly clear be a kind forward of discussed to I coming of readout there? going PFS. you've level? there I year. a know in XX% the is increase -- expecting go/no-go show What a to up this should But of set study we middle what kind kind guess, we up as this And data positive I then what be for I guess lastly, is

Michael H. Tardugno

going maybe can Hazard Dr. in. I'm and to conversation Yes, start jump this

So of evolution patients, cancer of we've this patients. trial, during of treatment seen the the an cancer course ovarian

Avastin the data not program. the from trial, the yet started was we when So in

or not as of Again, inhibitors of HRD -- treatments combination way was saw Avastin for approval, make design options treatments So trial. for Avastin those their and PARP one of in newly the neither the treatment we the the to adjuvant considered in included the diagnosed population. were patients subsequent

objective to we very the improvement achieve XX% population, a XX% have improvement, study an are changed these still show programs were is achieve that drugs powered in ethically assumptions recently in some maintenance So ITT patients of with these approved. of believe I to that to who been mean I the addition mean close. some our -- of or obviously, that included milestone important have our

Hazard not it a reason as analysis. the a have larger to to make bit kind a in last immunotherapies to X- better X-month or the to most I'll to, a relevant, and think whether XX%, we and to clinically particularly what little patients. treating more the here that's larger typical I this out alluded benefit in to than include -- see for much that In by not issue. indicated can a of think seeing would we're response I verified we probably if we're so ratio But right there's And stratified by Dr. hazard look is getting data, part, cancer PFS. point every prespecified see in parse medical the do that include study. OS But have specifically is not an we're make, the sense think clinician at any the be is a XX%, from is in community XX% to improvement material PFS The subgroup

a this being data reduce trial failure holistically of at that very So frankly, Hazard? got and to comfortable decisions with look from going III study of construct I in to the make coming able knowledge, forward. that you the that Do make on to risk, Phase think decisions -- we Dr. and the feel

Dr. Sebastien Hazard

this. I absolutely. has add to have nothing Yes, to

Michael H. Tardugno

look And Frankly, that this in with novel care of as treatment we a diagnosed evolving far. a we're and -- standard newly of standard seeing at patients data is a we're care. excited with so the an that

gives evaluate So that us little I some, I ways. not want opportunity a standard bit a appropriate don't -- but but call think, some more bit it the typically uncertainty, in little data to more to

David Bautz

Okay.

the taking Sounds good. I appreciate you questions.

Operator

comes Kemp Capital question next Markets. from with Brookline The Dolliver

Brian Kemp Dolliver

in sites for clarification. Beth Philadelphia, X you for second the XXX. which institution? Israel. One The just First, the mentioned -- And site was

Michael H. Tardugno

like to you're could upon of up patients major And a specifically bring clinical Israel healthy been programs. I if are companies administer set us, the is mean This all them by people. study them, focused and vaccine the research enrollment. It's for to vaccine find relied institution DM -- the it's into a for you evaluate vaccine to geared research that's online primarily high-quality way, the by the the clinical an mean patients well-regarded They of in institution I curious by Philadelphia. recommended this follow-up. and to

Brian Kemp Dolliver

Great.

relates The around second partnering particularly government. with to commentary your in question

presumably, move have of the potential a -- of So position that the evaluate. BARDA can move can to you would would state be who faster Because what and your very process? slowly. partners once you of that DoD And part in everyone is have other involved data

Michael H. Tardugno

out, typically a include you as question. that's are my any though biggest don't And that is in development process development that -- I good of consumer it not they just or that good decision competitive it. the the the -- a in apologize But saying may mean, Yes. of ways, -- low I I include pointed the even way. network, government because thinking old about of and kind that's of many boys this may and reality the mean there's for I always products

I from Goff had agree our well, guys. government. not the hope is or And focused interest development I as interest I will my will the delay Dr. We've pharma multiple to that's data -- had years in for not vaccine more investment suspect as but I have this of the patients can it's And vaccine, ongoing demonstrate to data, time. that pharma like of said that number not a a capability from if We've and we in that interest. a expectation heady Targeted days multiple see. only unique, they -- Product with least there's superiority, opportunity government although government, environment, for our But Profile assuming -- pending ago, will a make the We found in the conversations, this good I in kind important would characteristics over of we of with Le any good this ongoing meantime, community. products bring potent the will the financing mean the as a generated big mean, stronger provide wait completely. especially with companies. kind we for but the in be, the compelling. very have protection platform little TPP sense environment, at makes her people in other the be continuing this of not

our right, believe to in every patience payoff and our returns major that forward. company, hope And investment if that the on we're support we have reason way we're have from and -- investors... if the we -- I community the continued to investment right, So for we'll continue get make we'll as

Operator

for I session. question-and-answer remarks. to Tadano our concludes any closing over back the This like would to Michael conference turn

Michael H. Tardugno

we me I a let everyone could us. in thank first, be think joining position. better don't Well, for

on company seen programs. quite the bit our of -- progress in we a Your fundamentals, our of all have

We scientists very of a group have researchers. and excited

kind in the in complement of technologies on example. to studies for to proprietary continue intellectual We our the basis our and Phase -- that's important in early XXX, believe early talent of success. preclinical preliminary for I add We study a

that We these let the stimulating XXX, for recruiting, the we immune We say, potential system. entirety technologies. are the know the of -- it works technologies. know showing This me in in example,

in pathogens. promise excellent immuno-oncology the hold is virulent and technologies potential protection next-generation our a So against

from progress about a pencil Our very our coming used I and have providing being months. that exposure sure that cancer see, make very to progressing making we to indicated you is, ovarian options potential hope the We're sure remain is you Churchill And reporting sharp cash to work on data very we with general in Jeff the clinical trials in focused public's efficiently. our it excited pandemics with progresses. will and well. women as

We wish concludes for you you and you wonderful forward your remarks, on week and to great informed thank our our those again, and weekend. holiday for keeping a progress And holiday nice So attendance. the that celebrating operator.. And afternoon. look very a

Operator

The concluded. conference now has

may You disconnect.

Imunon (IMNN) 28 Mar 242023 Q4 Earnings call transcript